Skip to main content
OpenTrials
Completed

NCT Number: NCT04037722

Echocardiographic Changes After 3-hydroxy Butyrate+Whey Intake

This study evaluates the cardiovascular effects of adding the ketone body 3-hydroxy butyrate (3-OHB) to whey protein during human endotoxemia. Further, this study compares cardiovascular changes during healthy and catabolic conditions.

Participants will receive isocaloric, isonitrogenous beverages of either whey or 3-OHB+whey in a randomized crossover design during either healthy (overnight fast) or catabolic conditions (inflammation/endotoxemia + 36 h fast and bed rest).

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–40 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Medical Research Labarotory, DoH, Aarhus University Hospital

Aarhus, 8200, Denmark

About this study

Background: A newly published study found beneficial cardiovascular effects of 3-OHB infusion in a population with chronic heart failure, significantly increasing cardiac output. Similar effects on cardiac output were observed in healthy volunteers. These findings pave the way for 3-OHB as a therapeutic nutritional supplement, since it is well-absorbed during oral consumption. However, it is unknown whether the cardiovascular effects of 3-OHB persist during a sepsis-like catabolic state and when administered orally.

Aim: This study aims to investigate the cardiovascular effects of adding the ketone body 3-hydroxy butyrate (3-OHB) to whey protein during a human disease model, comprising endotoxemia + bed rest + fast.

Hypothesis:

  • Adding the ketone body 3-OHB to an oral protein supplement increases cardiac output measures
  • Catabolic stress (endotoxemia/inflammation + 36 h fast and bed rest) induces cardiovascular changes compared with healthy conditions (overnight fast)

Interventions:

In a randomized crossover design, eight healthy, lean, young men will undergo either:

i) Healthy conditions (overnight fast) + whey protein^

ii) Catabolic conditions (Inflammation (LPS) + 36-hour fast and bed rest*) + whey protein^

iii) Catabolic conditions (Inflammation (LPS) + 36-hour fast and bed rest*) + 3-OHB/whey protein^"

*LPS will be administered (1 ng/kg) the day prior to the study together with fast and bed rest. On the study day LPS (0.5 ng/kg) will be injected.

^Beverages will be isonitrogenous and isocaloric (fat will be added) with 45 g whey protein + 20 g maltodextrin. Bolus/sip administration will be applied (1/3 bolus, 1/2 sip)

" 50 grams of 3-OHB will be orally administered (1/2 bolus, 1/2 sip)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Between 20-40 years of age
  • Body mass index between 20-30 kg/m^2
  • Healthy
  • Oral and written consent forms obtained prior to study day

Exclusion criteria

  • Recent immobilization of an extremity that is not fully rehabilitated
  • Lactose, lidocain or rubber allergies
  • Current disease
  • Use of anabolic steroids
  • Smoking
  • Former major abdominal surgery (Or current problems with the GI tract)

•>10 hours of exercise/weak

  • Present ketogenic diets or high-protein diets
  • Blood doner that does not want to discontinue blood donations until study completion
  • Pending MR scan

Treatment and study plan

Whey

Dietary Supplement

45 g whey + 20 g maltodextrin

3-OHB + Whey

Dietary Supplement

50 g ketone + 45 g whey + 20 g maltodextrin

Primary outcomes

  1. Change in left ventricular outflow tract velocity time integral

    Time frame: Measured during the basal period and after 1.5 hours of intervention

    Echocardiographic changes in left ventricular outflow tract velocity time integral from the basal period and after 1.5 hours of intervention

Secondary outcomes

  1. Changes in Left Ventricular Ejection Fraction (LVEF)

    Time frame: Measured during the basal period and after 1.5 hours of intervention

    Echocardiographic changes in LVEF from the basal period and after 1.5 hours of intervention

  2. Changes in Global Longitudinal Strain (GLS)

    Time frame: Measured during the basal period and after 1.5 hours of intervention

    Echocardiographic changes in GLS from the basal period and after 1.5 hours of intervention

  3. Changes in S´ Max

    Time frame: Measured during the basal period and after 1.5 hours of intervention

    Echocardiographic changes in S´ Max from the basal period and after 1.5 hours of intervention

  4. Changes in blood pressure

    Time frame: Measured during the basal period and after 1.5 hours of intervention

    Changes in blood pressure from the basal period and after 1.5 hours of intervention

  5. Changes in heart rate

    Time frame: Measured during the basal period and after 1.5 hours of intervention

    Changes in heart rate from the basal period and after 1.5 hours of intervention

  6. Changes in axillary temperature

    Time frame: Measured during the basal period and after 1.5 hours of intervention

    Changes in axillary temperature from the basal period and after 1.5 hours of intervention

  7. Difference in Left Ventricular Ejection Fraction (LVEF) (Healthy vs catabolic conditions)

    Time frame: Measured after 2 hours of basal period

    Echocardiographic difference in LVEF during the basal period between healthy and catabolic conditions (a pooled mean of the two catabolic days, if there is no difference between the first and second time of LPS exposure)

  8. Difference in Global Longitudinal Strain (GLS) (Healthy vs catabolic conditions)

    Time frame: Measured after 2 hours of basal period

    Echocardiographic difference in GLS during the basal period between healthy and catabolic conditions (a pooled mean of the two catabolic days, if there is no difference between the first and second time of LPS exposure)

  9. Difference in S´ Max (Healthy vs catabolic conditions)

    Time frame: Measured after 2 hours of basal period

    Echocardiographic difference in S´ Max during the basal period between healthy and catabolic conditions (a pooled mean of the two catabolic days, if there is no difference between the first and second time of LPS exposure)

  10. Difference in axillary temperature (healthy vs catabolic)

    Time frame: Measured after 2 hours of basal period

    Difference in axillary temperature after 2 hours basal period between healthy and catabolic conditions (a pooled mean of the two catabolic days, if there is no difference between the first and second time of LPS exposure)

  11. Difference in heart rate (healthy vs catabolic)

    Time frame: Measured after 2 hours of basal period

    Difference in heart rate after 2 hours basal period between healthy and catabolic conditions (a pooled mean of the two catabolic days, if there is no difference between the first and second time of LPS exposure)

  12. Difference in blood pressure (healthy vs catabolic)

    Time frame: Measured after 2 hours of basal period

    Difference in blood pressure after 2 hours basal period between healthy and catabolic conditions (a pooled mean of the two catabolic days, if there is no difference between the first and second time of LPS exposure)

Sponsors and collaborators

Lead sponsor

University of Aarhus

Other

Collaborators

  • Aarhus University Hospital Skejby
  • Arla Foods

Registry information

Official study title

Echocardiographic Changes After Oral Intake of 3-hydroxy Butyrate+Whey in a Human Endotoxemia Model

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Jul 30, 2019
Registry last updated
Jun 11, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.